ArticleIntestinal Failure (New York, N.Y.)
Post-transplant lymphoproliferative disorder following multivisceral transplantation: Incidence, risk factors, and outcomes in an adult UK cohort.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post transplant lymphoproliferative disorder (PTLD) incidence is highest in patients undergoing intestinal and multivisceral transplantation (MVT). We describe our experience of PTLD in a large cohort of adult MVT patients. Materials and methods: We performed a retrospective cohort study of 163 consecutive patients undergoing intestinal and multivisceral transplantation with alemtuzumab based induction from 2007 to 2024. Clinical data were obtained from patient records. Univariate analyses were performed to assess factors associated with PTLD development. Results: Twenty-nine patients (17.8 %) developed PTLD, of which 28/29 (96.6 %) were EBV associated. Cumulative incidence of PTLD adjusting for competing risk of death was 14.1 %, 19.7 % and 24.9 % at 1, 5, and 10 years, respectively. In those who developed PTLD median time to development of EBV viraemia was 6.6 months. Median initial EBV viral load log was 3.6. EBV serology mismatch between donor/recipient was the only variable significantly associated with PTLD development (OR 7.7, CI 2.9-20.0, P < 0.001). All patients received rituximab monotherapy initially. Of patients who had end of treatment radiological assessment (n = 23), overall response rate to rituximab was 56.5 %. Conclusion: There is a high incidence of PTLD in patients within the first year post intestinal transplant. EBV matching status is a potentially modifiable risk factor for PTLD development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.